#USA #Robbins Geller #San Diego #Class Action #Soleno Therapeutics

Investor Alert for Soleno Therapeutics Inc. Investors

On March 7, 2026, Robbins Geller Rudman & Dowd LLP, a well-known law firm, announced an opportunity for those who purchased stock in Soleno Therapeutics, Inc. (NASDAQ: SLNO). Investors who acquired shares between March 26, 2025, and November 4, 2025, have until May 5, 2026, to appoint a lead plaintiff in a class action lawsuit. This legal action, titled City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., aims to address alleged violations of the Securities Exchange Act of 1934 by the company and its top executives.

Background on Soleno Therapeutics

Soleno Therapeutics is engaged in developing innovative treatments for rare diseases. Its primary product, diazoxide choline extended-release tablets (DCCR), is designed for treating hyperphagia in patients with Prader-Willi syndrome (PWS). However, during the class action lawsuit, it's alleged that critical safety concerns associated with DCCR were downplayed or concealed during clinical trials, raising grave risks for patients.

Allegations Against Soleno Therapeutics

The class action lawsuit outlines three main allegations:
1. Failure to Disclose Safety Issues: The plaintiffs claim that Soleno's Phase 3 clinical trial program for DCCR did not adequately report serious safety concerns, including significant fluid retention in clinical trial participants.
2. Misrepresentation of Drug Viability: It is asserted that DCCR's market viability was materially lower due to undisclosed risks, including potential adverse events post-launch, which could lead to regulatory scrutiny and consumer reluctance on the part of physicians prescribing the drug.
3. Impact of Negative Reports: Following critical findings made by Scorpion Capital LLC regarding DCCR, Soleno’s stock price saw a drastic decline—nearly 12% within two days of the report's release. This was accompanied by reports of a patient's death related to DCCR usage, causing an additional 19% drop in stock price shortly thereafter.

Seeking Lead Plaintiffs

Under the Private Securities Litigation Reform Act of 1995, investors affected by the company's actions during the specified class period can seek to be appointed as lead plaintiffs. The lead plaintiffs play a crucial role, representing the wider group of investors in directing the class action lawsuit. Notably, an investor's chances to recover from the lawsuit aren't dependent on their status as a lead plaintiff, meaning every affected investor has a stake in the proceedings.

Representation by Robbins Geller

Robbins Geller is recognized as a leader in securities fraud and shareholder rights litigation, with substantial successes in the past. The firm has recovered over $916 million for investors as of 2025, making it a significant player in this legal arena. Their experience equips them to effectively navigate complex securities cases and advocate vigorously for their clients.

Conclusion

Investors in Soleno Therapeutics facing significant financial losses have a pathway to seek restitution through this class action lawsuit. With the approaching deadline of May 5, 2026, it's crucial for affected investors to act quickly, gather necessary information, and consider participation in this landmark case. The implications of the underlying allegations are profound, potentially transforming how future pharmaceutical products are scrutinized and brought to market. For those interested in joining the lawsuit, more information can be obtained directly from Robbins Geller through their dedicated channels.